Table 1.
Clinical characteristics
| Patient characteristics | n (%) |
|---|---|
| Patient demographics | 15 |
| Average age ± SD, years | 45.20 ± 7.06 |
| BMI ± SD, kg/m2 | 24.80 ± 4.58 |
| Smoking | 0 (0.00) |
| Diabetes | 0 (0.00) |
| Obese | 2 (13.33) |
| Neoadjuvant chemotherapy | 3 (20.00) |
| Prior radiation | 1 (6.67) |
| Oncologic characteristicsa | |
| BRCA carrier | 1 (6.67) |
| PALB2 carrier | 0 (0.00) |
| PTEN carrier | 0 (0.00) |
| Negative genetic testing | 8 (53.33) |
| IDCb | 8 (42.11) |
| Grade 1 | 2 (25.00) |
| Grade 2 | 2 (25.00) |
| Grade 3 | 4 (50.00) |
| DCISb | 15 (78.95) |
| Grade 1 | 0 (0.00) |
| Grade 2 | 5 (33.33) |
| Grade 3 | 10 (66.67) |
| T-size | |
| T1 | 9 (60.00) |
| T2 | 3 (20.00) |
| T3 | 2 (13.33) |
| Unknown | 1 (6.67) |
| Nodal status | |
| N0 | 9 (60.00) |
| N1 | 1 (6.67) |
| N2 | 2 (13.33) |
| N3 | 1 (6.67) |
| Unknown | 2 (13.33) |
| Sentinel node biopsy | 11 (73.33) |
| Axillary lymph node dissection | 3 (20.00) |
| Procedure laterality | |
| Unilateral | 11 (73.33) |
| Bilateral | 4 (26.67) |
| Implant placementb | |
| Pre-pectoral | 11 (57.90) |
| Subpectoral | 8 (42.10) |
| Mastectomy type | |
| Skin-Sparing | 4 (26.67) |
| Nipple-Sparing | 11 (73.33) |
| Reconstruction stageb | |
| Single-stage (DTI) | 11 (57.90) |
| Two-stage (TE) | 8 (42.10) |
SD standard deviation, BMI body mass index, IDC invasive ductal carcinoma, DCIS ductal carcinoma in-situ, DTI direct-to-implant, TE tissue expander
aGiven variability in time interval of pathologic evaluation, oncotype for 4 cases were recorded per core needle biopsy. Additionally, genetic testing results were for 4 patients were unknown given short follow-up duration
bDenotes data presented by breast (n = 19)